To sum up, based on our preliminary investigation, the combination of GLS-010 plus lenvatinib and chemotherapy (XELOX) demonstrated an acceptable safety profile with promising anti-tumor efficacy in HER2-negative AFPGC. The gene discussed is ERBB2; the disease is neoplasm.